Insider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $53,250.00 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total value of $53,250.00. Following the completion of the transaction, the chief executive officer now directly owns 120,695 shares in the company, valued at $1,285,401.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, August 12th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $11.53, for a total value of $57,650.00.
• On Wednesday, July 10th, Richard Nolan Townsend sold 26,969 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $16.50, for a total transaction of $444,988.50.

Lexeo Therapeutics Stock Down 2.0 %

Shares of NASDAQ:LXEO opened at $9.67 on Friday. The firm has a market capitalization of $318.58 million and a P/E ratio of -0.43. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.38 and a current ratio of 9.38. The stock has a 50 day moving average price of $12.21 and a 200-day moving average price of $13.85. Lexeo Therapeutics, Inc. has a 52-week low of $9.00 and a 52-week high of $22.33.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.64). As a group, equities research analysts anticipate that Lexeo Therapeutics, Inc. will post -2.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Chardan Capital reissued a “buy” rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a report on Wednesday, August 14th. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. Robert W. Baird assumed coverage on Lexeo Therapeutics in a research report on Thursday, June 13th. They set an “outperform” rating and a $28.00 price target for the company. Baird R W upgraded Lexeo Therapeutics to a “strong-buy” rating in a research report on Thursday, June 13th. Finally, HC Wainwright decreased their target price on Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $22.14.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Eventide Asset Management LLC purchased a new stake in Lexeo Therapeutics in the fourth quarter worth about $40,298,000. Omega Fund Management LLC bought a new stake in Lexeo Therapeutics in the fourth quarter worth $28,955,000. Blackstone Inc. purchased a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $9,342,000. RA Capital Management L.P. bought a new position in shares of Lexeo Therapeutics during the first quarter valued at $10,364,000. Finally, Janus Henderson Group PLC raised its position in shares of Lexeo Therapeutics by 9.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock worth $39,802,000 after purchasing an additional 210,047 shares during the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.